Pfenex Announces Management Change
November 13 2019 - 4:40PM
Pfenex Inc. (NYSE American: PFNX), today announced that Susan
Knudson has resigned for personal reasons from her role as Senior
Vice President, Chief Financial Officer effective November 13,
2019, but will continue to support the company by providing
transition services until February 1, 2020. The company is
conducting a search for a successor.
“We appreciate Susan’s contributions to Pfenex and her work with
the finance team during the past years in which we transformed
Pfenex, ultimately leading to our FDA approval for PF708, a
potential therapeutic equivalent to Forteo®,” said Eef
Schimmelpennink, Chief Executive Officer of Pfenex. “Susan’s
efforts have been key to our success, and we wish her all the best
going forward.”
Ms. Knudson said, “My time at Pfenex has been rewarding. I have
been particularly honored to have helped build the company
alongside Pfenex’s many dedicated employees. I am confident that
the Pfenex team’s focus and capability will continue to drive
success and build value for our stockholders, and I wish them great
success.”
About Pfenex Inc.
Pfenex is a development and licensing biotechnology company
focused on leveraging its Pfēnex Expression Technology® to
develop and improve protein therapies for unmet patient needs.
Using the patented Pfēnex Expression Technology platform,
Pfenex has created an advanced pipeline of potential therapeutic
equivalents, and vaccines. Pfenex’s lead product candidate is
PF708, a therapeutic equivalent candidate to Forteo® (teriparatide
injection). PF708 has been approved in the U.S. for the treatment
of osteoporosis in certain patients at high risk of fracture, and
marketing authorization applications are pending in other
jurisdictions. In addition, Pfenex is developing
hematology/oncology products in collaboration with Jazz
Pharmaceuticals, including PF743, a recombinant crisantaspase, and
PF745, a recombinant crisantaspase with half-life extension
technology. Pfenex also uses its Pfēnex Expression Technology
platform to produce CRM197, a diphtheria toxoid carrier protein
used in prophylactic and therapeutic vaccines.
Pfenex investors and others should note that Pfenex announces
material information to the public about Pfenex through a variety
of means, including its website (http://www.pfenex.com/), its
investor relations website (http://pfenex.investorroom.com/), press
releases, SEC filings, public conference calls, corporate Twitter
account (https://twitter.com/pfenex), Facebook page
(https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/),
and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in
order to achieve broad, non-exclusionary distribution of
information to the public and to comply with its disclosure
obligations under Regulation FD. Pfenex encourages its investors
and others to monitor and review the information Pfenex makes
public in these locations as such information could be deemed to be
material information. Please note that this list may be updated
from time to time.
Cautionary Note Regarding Forward-Looking
Statement
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements generally relate to future events
or Pfenex's future financial or operating performance. In some
cases, you can identify forward-looking statements because they
contain words such as “may,” “will,” “should,” “expects,” “plans,”
“anticipates,” “could,” “intends,” “target,” “projects,”
“contemplates,” “believes,” “estimates,” “predicts,” “potential” or
“continue” or the negative of these words or other similar terms or
expressions that concern Pfenex's future expectations, strategy,
plans or intentions. Forward-looking statements in this press
release include, but are not limited to, statements regarding
Pfenex’s belief that Susan Knudson will continue to provide
transition services through February 2020. Pfenex's
expectations and beliefs regarding these matters may not
materialize, and actual results in future periods are subject to
risks and uncertainties that could cause actual results to differ
materially from those projected. Information on risks,
uncertainties, and other information affecting Pfenex's business
and operating results is contained in Pfenex’s Quarterly Report on
Form 10-Q for the quarter ended September 30, 2019 and in its other
filings with the Securities and Exchange Commission. The
forward-looking statements in this press release are based on
information available to Pfenex as of the date hereof, and Pfenex
disclaims any obligation to update any forward-looking statements,
except as required by law.
Hans Vitzthum
Managing Director
LifeSci Advisors, LLC.
1 International Place, Suite 1480
Boston, MA, 02110
Office: 617-430-7578
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Apr 2023 to Apr 2024